Drug Translation and Development

$139,415U19FY2013AINIH

University Of Rochester, Rochester NY

Investigators

Linked publications & trials

Paper 37237442 Paper 34253059 Paper 34153091 Paper 33340449 Paper 31996462 Paper 31827187 Paper 31329495 Paper 31168092 Paper 31020321 Paper 30238842 Paper 30224802 Paper 30115997 Paper 29332538 Paper 29288597 Paper 28978810 Paper 28534660 Paper 28463588 Paper 28004802 Paper 27905869 Paper 27841740 Paper 27710703 Paper 27539247 Paper 27478169 Paper 27332954 Paper 26842770 Paper 26632857 Paper 26571397 Paper 26397175 Paper 26254422 Paper 26114328 Paper 26068482 Paper 25696837 Paper 25627812 Paper 25564716 Paper 25351294 Paper 25228985 Paper 25083740 Paper 24991028 Paper 24989701 Paper 24889886 Paper 24831696 Paper 24827855 Paper 24735964 Paper 24616422 Paper 24482184 Paper 24183780 Paper 24101231 Paper 24059681 Paper 24047412 Paper 24007881 Paper 23797667 Paper 23621375 Paper 23509002 Paper 23496054 Paper 23299616 Paper 23281399 Paper 23195776 Paper 23169593 Paper 23039852 Paper 23002435 Paper 22955916 Paper 22889760 Paper 22792383 Paper 22596259 Paper 22262765 Paper 22252623 Paper 22198183 Paper 21957195 Paper 21903897 Paper 21902610 Paper 21574903 Paper 21417595 Paper 21291953 Paper 21275606 Paper 20171510

Abstract

The main goal of the Drug Translation and Development Core Is to facilitate each scientific project in the development of potential radiation mitigators for various organ systems, including lung (Project 1), CNS (Project 2), skin (Project 3), and bone marrow (Project 4) in the context of a total body radiation exposure. This Core will monitor the progress of testing these agents with respect to the efficacy, safety, toxicology, pharmacokinetics, pharmacodynamics, and quality assurance. As a result, Core D hopes to be able to make recommendations regarding regulatory requirement and, ultimately, will be in a position to recommend strategies towards the development of clinical studies and ultimate drug approval by FDA.

View original record on NIH RePORTER →